Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy

Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.